/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Company Overview Aspira Women s Health Inc. is dedicated to the discovery, development, and commercialization of noninvasive, AI-powered tests to aid in the diagnosis of gynecologic diseases, starting with ovarian cancer. We plan to broaden our focus to the differential diagnosis of other gynecologic diseases that typically cannot be assessed through traditional non-invasive clinical procedures.
The business is unprofitable at the operating level (-2307.00% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 8475.0% YoY with margins expanding 404643.0pp.
Negative free cash flow of -$7M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$223K
▲ +8475.0% YoY
Net Income (TTM)
-$10M
▲ +2.4% YoY
Op. Margin
-3094.62%
▲ +404643.0pp YoY
ROIC
-167.55%
▲ +211.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$5M
▲ +42.0% YoY
Op. Cash Flow (TTM)
-$5M
▲ +42.0% YoY
Net Debt
$3M
Cash & Equiv.
$477K
5Y CAGR: -40.6%
Continue Research
SourceComputed from the 10-Q filed 14 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 15 Aug 2026. How this is calculated.
Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.